Traynor Capital Management, Inc. Amgen Inc Transaction History

Traynor Capital Management, Inc.

$1.6 Billion
Q3 2024

A detailed history of Traynor Capital Management, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 648 shares of AMGN stock, worth $171,389. This represents 0.01% of its overall portfolio holdings.

Number of Shares

648

Previous 674 3.86%

Holding current value

$171,389

Previous $210,000 0.95%

% of portfolio

0.01%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$309.38 - $337.38 $8,043 - $8,771	-26 Reduced 3.86%	648 $208,000
Q2 2024 Jul 24, 2024	SELL	$262.75 - $319.31 $5.16 Million - $6.27 Million	-19,625 Reduced 96.68%	674 $210,000
Q1 2024 Apr 12, 2024	BUY	$268.87 - $324.56 $365,125 - $440,752	1,358 Added 7.17%	20,299 $5.77 Million
Q4 2023 Jan 18, 2024	BUY	$255.7 - $288.46 $421,905 - $475,958	1,650 Added 9.54%	18,941 $5.46 Million
Q3 2023 Oct 16, 2023	BUY	$218.65 - $271.46 $228,270 - $283,404	1,044 Added 6.43%	17,291 $4.65 Million
Q2 2023 Jul 28, 2023	SELL	$214.27 - $253.37 $38,354 - $45,353	-179 Reduced 1.09%	16,247 $3.61 Million
Q1 2023 Apr 21, 2023	SELL	$225.79 - $275.2 $35,900 - $43,756	-159 Reduced 0.96%	16,426 $3.97 Million
Q4 2022 Jan 27, 2023	SELL	$229.03 - $291.01 $52,218 - $66,350	-228 Reduced 1.36%	16,585 $0
Q3 2022 Nov 15, 2022	BUY	$224.46 - $253.15 $2.45 Million - $2.76 Million	10,902 Added 184.44%	16,813 $3.79 Million
Q3 2022 Oct 20, 2022	SELL	$224.46 - $253.15 $2.43 Million - $2.74 Million	-10,805 Reduced 64.64%	5,911 $1.33 Million
Q2 2022 Jul 28, 2022	SELL	$230.71 - $256.74 $300,615 - $334,532	-1,303 Reduced 7.23%	16,716 $4.07 Million
Q1 2022 Apr 13, 2022	BUY	$219.27 - $242.57 $4,823 - $5,336	22 Added 0.12%	18,019 $4.36 Million
Q4 2021 Feb 01, 2022	SELL	$198.88 - $227.6 $1,591 - $1,820	-8 Reduced 0.04%	17,997 $4.05 Million
Q3 2021 Oct 25, 2021	SELL	$212.27 - $248.7 $26,958 - $31,584	-127 Reduced 0.7%	18,005 $3.83 Million
Q2 2021 Jul 21, 2021	BUY	$233.58 - $259.14 $89,461 - $99,250	383 Added 2.16%	18,132 $4.51 Million
Q1 2021 May 04, 2021	BUY	$221.91 - $258.6 $135,808 - $158,263	612 Added 3.57%	17,749 $4.42 Million
Q4 2020 Jan 14, 2021	SELL	$216.38 - $257.67 $274,586 - $326,983	-1,269 Reduced 6.89%	17,137 $3.94 Million
Q3 2020 Oct 26, 2020	BUY	$234.65 - $260.95 $146,421 - $162,832	624 Added 3.51%	18,406 $4.18 Million
Q2 2020 Aug 10, 2020	BUY	$197.81 - $242.74 $384,740 - $472,129	1,945 Added 12.28%	17,782 $4.19 Million
Q1 2020 Apr 29, 2020	BUY	$182.24 - $241.7 $151,441 - $200,852	831 Added 5.54%	15,837 $3.21 Million
Q4 2019 Jan 24, 2020	BUY	$189.21 - $243.2 $25,921 - $33,318	137 Added 0.92%	15,006 $3.62 Million
Q3 2019 Nov 01, 2019	BUY	$174.11 - $208.62 $215,374 - $258,062	1,237 Added 9.07%	14,869 $2.88 Million
Q2 2019 Jul 26, 2019	SELL	$166.7 - $195.41 $41,174 - $48,266	-247 Reduced 1.78%	13,632 $2.54 Million
Q1 2019 Apr 12, 2019	BUY	$180.87 - $203.88 $223,193 - $251,587	1,234 Added 9.76%	13,879 $2.64 Million
Q4 2018 Jan 24, 2019	BUY	$178.4 - $208.25 $220,680 - $257,605	1,237 Added 10.84%	12,645 $2.46 Million
Q3 2018 Oct 24, 2018	BUY	$185.29 - $208.89 $158,422 - $178,600	855 Added 8.1%	11,408 $2.36 Million
Q2 2018 Aug 03, 2018	BUY	$166.05 - $186.51 $186,474 - $209,450	1,123 Added 11.91%	10,553 $1.95 Million
Q1 2018 May 01, 2018	BUY	$169.43 - $198.0 $196,030 - $229,086	1,157 Added 13.99%	9,430 $1.61 Million
Q4 2017 Feb 01, 2018	BUY	$168.79 - $188.59 $379,439 - $423,950	2,248 Added 37.31%	8,273 $1.44 Million
Q3 2017 Oct 27, 2017	BUY	$167.29 - $191.0 $1.01 Million - $1.15 Million	6,025	6,025 $1.12 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Traynor Capital Management, Inc. with notifications on news.

Account

Traynor Capital Management, Inc. Amgen Inc Transaction History